vs
Side-by-side financial comparison of ManpowerGroup Inc. (MAN) and Zoetis (ZTS). Click either name above to swap in a different company.
ManpowerGroup Inc. is the larger business by last-quarter revenue ($4.7B vs $2.4B, roughly 2.0× Zoetis). Zoetis runs the higher net margin — 25.3% vs 0.6%, a 24.6% gap on every dollar of revenue. On growth, ManpowerGroup Inc. posted the faster year-over-year revenue change (7.1% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $168.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 3.5%).
ManpowerGroup is an American multinational corporation headquartered in Milwaukee, Wisconsin. Founded in 1948 by Elmer Winter and Aaron Scheinfeld, ManpowerGroup is the third-largest staffing firm in the world behind Swiss firm Adecco and Dutch firm Randstad NV. The company provides administrative & support services, professional services, and business services through its four primary brands: Manpower, Experis, Right Management, and ManpowerGroup Solutions.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
MAN vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.7B | $2.4B |
| Net Profit | $30.2M | $603.0M |
| Gross Margin | 16.3% | 70.2% |
| Operating Margin | 1.7% | 31.9% |
| Net Margin | 0.6% | 25.3% |
| Revenue YoY | 7.1% | 3.0% |
| Net Profit YoY | 34.2% | 3.8% |
| EPS (diluted) | $0.65 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.7B | $2.4B | ||
| Q3 25 | $4.6B | $2.4B | ||
| Q2 25 | $4.5B | $2.5B | ||
| Q1 25 | $4.1B | $2.2B | ||
| Q4 24 | $4.4B | $2.3B | ||
| Q3 24 | $4.5B | $2.4B | ||
| Q2 24 | $4.5B | $2.4B | ||
| Q1 24 | $4.4B | $2.2B |
| Q4 25 | $30.2M | $603.0M | ||
| Q3 25 | $18.0M | $721.0M | ||
| Q2 25 | $-67.1M | $718.0M | ||
| Q1 25 | $5.6M | $631.0M | ||
| Q4 24 | $22.5M | $581.0M | ||
| Q3 24 | $22.8M | $682.0M | ||
| Q2 24 | $60.1M | $624.0M | ||
| Q1 24 | $39.7M | $599.0M |
| Q4 25 | 16.3% | 70.2% | ||
| Q3 25 | 16.6% | 71.5% | ||
| Q2 25 | 16.9% | 73.6% | ||
| Q1 25 | 17.1% | 72.0% | ||
| Q4 24 | 17.2% | 69.5% | ||
| Q3 24 | 17.3% | 70.6% | ||
| Q2 24 | 17.4% | 71.7% | ||
| Q1 24 | 17.3% | 70.6% |
| Q4 25 | 1.7% | 31.9% | ||
| Q3 25 | 1.4% | 37.0% | ||
| Q2 25 | -0.6% | 36.7% | ||
| Q1 25 | 0.7% | 36.5% | ||
| Q4 24 | 1.6% | 31.6% | ||
| Q3 24 | 1.6% | 36.6% | ||
| Q2 24 | 2.2% | 33.0% | ||
| Q1 24 | 1.5% | 34.1% |
| Q4 25 | 0.6% | 25.3% | ||
| Q3 25 | 0.4% | 30.0% | ||
| Q2 25 | -1.5% | 29.2% | ||
| Q1 25 | 0.1% | 28.4% | ||
| Q4 24 | 0.5% | 25.1% | ||
| Q3 24 | 0.5% | 28.6% | ||
| Q2 24 | 1.3% | 26.4% | ||
| Q1 24 | 0.9% | 27.4% |
| Q4 25 | $0.65 | $1.37 | ||
| Q3 25 | $0.38 | $1.63 | ||
| Q2 25 | $-1.44 | $1.61 | ||
| Q1 25 | $0.12 | $1.41 | ||
| Q4 24 | $0.49 | $1.29 | ||
| Q3 24 | $0.47 | $1.50 | ||
| Q2 24 | $1.24 | $1.37 | ||
| Q1 24 | $0.81 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $871.0M | — |
| Total DebtLower is stronger | $1.1B | — |
| Stockholders' EquityBook value | $2.1B | $3.3B |
| Total Assets | $9.2B | $15.5B |
| Debt / EquityLower = less leverage | 0.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $871.0M | — | ||
| Q3 25 | $274.6M | $2.1B | ||
| Q2 25 | $289.8M | $1.4B | ||
| Q1 25 | $395.0M | $1.7B | ||
| Q4 24 | $509.4M | $2.0B | ||
| Q3 24 | $410.9M | $1.7B | ||
| Q2 24 | $468.9M | $1.6B | ||
| Q1 24 | $604.8M | $2.0B |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $468.3M | — | ||
| Q2 25 | $470.3M | — | ||
| Q1 25 | $971.4M | — | ||
| Q4 24 | $929.4M | — | ||
| Q3 24 | $999.7M | — | ||
| Q2 24 | $961.7M | — | ||
| Q1 24 | $968.9M | — |
| Q4 25 | $2.1B | $3.3B | ||
| Q3 25 | $2.0B | $5.4B | ||
| Q2 25 | $2.0B | $5.0B | ||
| Q1 25 | $2.1B | $4.7B | ||
| Q4 24 | $2.1B | $4.8B | ||
| Q3 24 | $2.2B | $5.2B | ||
| Q2 24 | $2.1B | $5.0B | ||
| Q1 24 | $2.2B | $5.1B |
| Q4 25 | $9.2B | $15.5B | ||
| Q3 25 | $8.4B | $15.2B | ||
| Q2 25 | $8.5B | $14.5B | ||
| Q1 25 | $8.0B | $14.1B | ||
| Q4 24 | $8.2B | $14.2B | ||
| Q3 24 | $8.5B | $14.4B | ||
| Q2 24 | $8.5B | $14.2B | ||
| Q1 24 | $8.5B | $14.3B |
| Q4 25 | 0.51× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.46× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $178.9M | $893.0M |
| Free Cash FlowOCF − Capex | $168.0M | $732.0M |
| FCF MarginFCF / Revenue | 3.6% | 30.7% |
| Capex IntensityCapex / Revenue | 0.2% | 6.7% |
| Cash ConversionOCF / Net Profit | 5.92× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-161.4M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $178.9M | $893.0M | ||
| Q3 25 | $59.8M | $938.0M | ||
| Q2 25 | $-189.6M | $486.0M | ||
| Q1 25 | $-153.2M | $587.0M | ||
| Q4 24 | $247.6M | $905.0M | ||
| Q3 24 | $83.5M | $951.0M | ||
| Q2 24 | $-137.9M | $502.0M | ||
| Q1 24 | $116.0M | $595.0M |
| Q4 25 | $168.0M | $732.0M | ||
| Q3 25 | $44.7M | $805.0M | ||
| Q2 25 | $-207.2M | $308.0M | ||
| Q1 25 | $-166.9M | $438.0M | ||
| Q4 24 | $236.3M | $689.0M | ||
| Q3 24 | $67.4M | $784.0M | ||
| Q2 24 | $-149.8M | $370.0M | ||
| Q1 24 | $104.2M | $455.0M |
| Q4 25 | 3.6% | 30.7% | ||
| Q3 25 | 1.0% | 33.5% | ||
| Q2 25 | -4.6% | 12.5% | ||
| Q1 25 | -4.1% | 19.7% | ||
| Q4 24 | 5.4% | 29.7% | ||
| Q3 24 | 1.5% | 32.8% | ||
| Q2 24 | -3.3% | 15.7% | ||
| Q1 24 | 2.4% | 20.8% |
| Q4 25 | 0.2% | 6.7% | ||
| Q3 25 | 0.3% | 5.5% | ||
| Q2 25 | 0.4% | 7.2% | ||
| Q1 25 | 0.3% | 6.7% | ||
| Q4 24 | 0.3% | 9.3% | ||
| Q3 24 | 0.4% | 7.0% | ||
| Q2 24 | 0.3% | 5.6% | ||
| Q1 24 | 0.3% | 6.4% |
| Q4 25 | 5.92× | 1.48× | ||
| Q3 25 | 3.32× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | -27.36× | 0.93× | ||
| Q4 24 | 11.00× | 1.56× | ||
| Q3 24 | 3.66× | 1.39× | ||
| Q2 24 | -2.29× | 0.80× | ||
| Q1 24 | 2.92× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAN
| Other | $2.4B | 52% |
| Transferred Over Time | $1.1B | 24% |
| Staffingand Interim | $1.0B | 22% |
| Productsand Services Other | $50.8M | 1% |
| Permanent Recruitment | $37.5M | 1% |
| Outcome Based Solutionsand Consulting | $20.7M | 0% |
| Transferred At Point In Time | $20.4M | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
